Efficacy Safety of Granulocyte Colony-stimulating Factor Treatment Children and Adolescents With Muscular Dystrophy

Overview

Importance: Currently the gold standard treatment for ambulant patients is corticosteroids. Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of satellite cells, the regulation of myoblast proliferation, and the differentiation and promotion of muscle regeneration and repair. Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy , Fascioscapulohumeral dystrophy. Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies will be included in an open study. Patients wheelchair-bound and and mobile and self-independent can participate in the study. Patients also treated with steroids can participate in this study. Clinical examination and physiotherapeutic and laboratory tests will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days during the 1st, 2nd, 3rd. 6th and 12th months. Manual muscle testing (Lovett test) of the upper and lower extremities, isometric force with the hand dynamometer, and the 6MWT (six minute walk test) are measured before and after therapy.

Full Title of Study: “Efficacy and the Safety of Granulocyte Colony-stimulating Factor Treatment in Children and Adolescents With Muscular Dystrophy: An Open Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2021

Detailed Description

Importance: Currently the gold standard treatment for ambulant patients is corticosteroids. Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of satellite cells, the regulation of myoblast proliferation, and the differentiation and promotion of muscle regeneration and repair. Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy , Fascioscapulohumeral dystrophy. Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies will be included in an open study. Patients wheelchair-bound and and mobile and self-independent can participate in the study. Patients also treated with steroids can participate in this study. Clinical examination and physiotherapeutic and laboratory tests will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days during the 1st, 2nd, 3rd. 6th and 12th months. Blood is sampled before G-CSF administration and on the 5th day of each treatment cycle. During each cycle of G-CSF administration physical therapy is also applied. Abdominal ultrasonography with a spleen assessment is performed before and after 7 days of G-CSF administration. Spirometry and electrocardiographic record are also performed. Side effects of G-CSF treatment will be assessed. Manual muscle testing (Lovett test) of the upper and lower extremities, isometric force with the hand dynamometer, and the 6MWT (six minute walk test) are measured before and after therapy. MRI of the gastrocnemius muscles will performed at the beginning and at the end of therapy.

Interventions

  • Drug: Granulocyte colony-stimulating factor (Filgrastim)
    • Drug administration

Arms, Groups and Cohorts

  • Other: Granulocyte colony-stimulating factor
    • Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy

Clinical Trial Outcome Measures

Primary Measures

  • Safety based on number of participants with adverse events.
    • Time Frame: Seven years
    • Adverse events will be monitored and scored for severity and related to the Granulocyte Colony-Stimulating Factor administration.

Secondary Measures

  • Muscle strength in patients with muscular dystrophy
    • Time Frame: Seven years
    • The assessment of muscle strength of the upper and lower limbs by Lovett test. The evaluation isometric force of upper limbs with the hand dynamometer. Distance measurement in a 6-minute walk test (6MWT) by feet or wheelchair,6MWT before and after therapy.
  • Laboratory investigations in patients with muscular dystrophy
    • Time Frame: Seven years
    • Blood count: Red blood cells 10^6/µL; Hemoglobin g/dl, Leucocytes 10^3/µL, Platelets 10^3/µL; biochemistry CRP – C Reactive Protein – mg/L; creatinine – mg/dL; glucose mg/dL, electrolytes, AST- U/L; ALT – U/L; cholesterol mg/dL; fibrinogen – mg/dL, partial thromboplastin time – sec; prothrombin time – sec, creatine kinase – U/L
  • Abdominal ultrasonography in patients with muscular dystrophy
    • Time Frame: Seven years
    • Abdominal ultrasonography with a spleen measurement will be done before and after G-CSF administration
  • Electrocardiographic records in patients with muscular dystrophy
    • Time Frame: Seven years
    • Electrocardiographic records wiil ibe done in patients with muscular Dystrophy before and after G-CSF administration.

Participating in This Clinical Trial

Inclusion Criteria

  • Muscular dystrophy – Duchenne muscular dystrophy, Becker muscular dystrophy, Fascioscapulohumeral dystrophy – age 5-15 Exclusion Criteria:

  • non- muscular dystrophy – age below 5 years – age over 15 years

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: 15 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medical University of Bialystok
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Wojciech Kulak, MD,PhD,Prof, Principal Investigator, Medical University of Bialystok, Bialystok, Poland
  • Overall Contact(s)
    • Wojciech Kulak, MD,PhD,Prof, +48603512723, kneur2@wp.pl

Citations Reporting on Results

Sienkiewicz D, Kulak W, Paszko-Patej G, Okurowska-Zawada B, Sienkiewicz J, Kulak P. Biochemical Changes in Blood of Patients with Duchenne Muscular Dystrophy Treated with Granulocyte-Colony Stimulating Factor. Biomed Res Int. 2019 Mar 13;2019:4789101. doi: 10.1155/2019/4789101. eCollection 2019.

Sienkiewicz D, Kulak W, Okurowska-Zawada B, Paszko-Patej G, Wojtkowski J, Sochon K, Kalinowska A, Okulczyk K, Sienkiewicz J, McEachern E. Efficacy and the Safety of Granulocyte Colony-Stimulating Factor Treatment in Patients with Muscular Dystrophy: A Non-Randomized Clinical Trial. Front Neurol. 2017 Oct 26;8:566. doi: 10.3389/fneur.2017.00566. eCollection 2017.

Eljaszewicz A, Sienkiewicz D, Grubczak K, Okurowska-Zawada B, Paszko-Patej G, Miklasz P, Singh P, Radzikowska U, Kulak W, Moniuszko M. Effect of Periodic Granulocyte Colony-Stimulating Factor Administration on Endothelial Progenitor Cells and Different Monocyte Subsets in Pediatric Patients with Muscular Dystrophies. Stem Cells Int. 2016;2016:2650849. doi: 10.1155/2016/2650849. Epub 2015 Dec 6.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.